ArticleBlood cancer journal2025

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.

Pralay Mukhopadhyay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.